Table 1 Characteristics of enrolled patients and treatment (N = 16)
Characteristics | Total, n (%) | Retrospectively enrolled, n (%) | Prospectively enrolled, n (%) | P value |
|---|---|---|---|---|
Median age, years (range) | 57 (43–74) | 65 (52–74) | 55 (43–68) | 0.05 |
Gender | 0.192 | |||
Male | 7 (43.8) | 3 (18.8) | 4 (25.0) | |
Female | 9 (56.3) | 1 (6.3) | 8 (50.0) | |
Pathological stage | 0.450 | |||
III | 2 (12.5) | 1 (6.3) | 1 (6.3) | |
IV | 14 (87.5) | 3 (18.8) | 11 (68.8) | |
ECOG PS score | 0.755 | |||
0 | 4 (25.0) | 1(6.3) | 3 (18.8) | |
1 | 12 (75.0) | 3 (18.8) | 9 (56.3) | |
Smoking status | 0.365 | |||
Nonsmoker | 11 (68.8) | 2 (12.5) | 9 (56.3) | |
Smoker/former smoker | 5 (31.3) | 2 (12.5) | 3 (18.8) | |
Histology | 0.750 | |||
Adenocarcinoma | 15 (93.8) | 4 (25.0) | 11 (68.8) | |
Adenosquamous carcinoma | 1 (6.3) | 0 (0) | 1 (6.3) | |
Metastatic sites | 0.641 | |||
Single site metastasis | 8 (50.0) | 2 (12.5) | 6 (37.5) | |
Multiple site metastasis | 6 (37.5) | 1 (6.3) | 5 (31.3) | |
No distant metastasis | 2 (12.5) | 1 (6.3) | 1 (6.3) | |
Brain metastasis | 0.608 | |||
Yes | 7 (43.8) | 2 (12.5) | 5 (31.3) | |
No | 9 (56.3) | 2 (12.5) | 7 (43.8) | |
EGFR mutation | 0.859 | |||
18 G719X | 4 (25.0) | 0 (0) | 4(25.0) | |
18 G719X + 18 E709X | 3 (18.8) | 1 (6.3) | 2 (12.5) | |
18 G719X + 20 S768I | 2 (12.5) | 1 (6.3) | 1 (6.3) | |
19 delins | 1 (6.3) | 0 (0) | 1 (6.3) | |
21 L833V/H835L | 2 (12.5) | 1 (6.3) | 1 (6.3) | |
21 L861Q | 4 (25.0) | 1 (6.3) | 3 (18.8) | |
PD-L1 expression | 0.550 | |||
≥ 1% | 2 (12.5) | 0 (0) | 2 (12.5) | |
< 1% | 14 (87.5) | 4 (25.0) | 10 (62.5) | |
Accompanying mutation | 0.392 | |||
Yes | 9 (56.3) | 3 (19.8) | 6 (37.5) | |
No | 7 (43.8) | 1 (6.3) | 6 (37.5) | |
Initial dosage of dacomitinib | 0.755 | |||
30 mg | 4 (25.0) | 1(6.3) | 3 (18.8) | |
45 mg | 12 (75.0) | 3 (18.8) | 9 (56.3) | |
Dose Reduction | 0.511 | |||
Yes | 6 (37.5) | 1 (6.3) | 5 (31.3) | |
No | 10 (62.5) | 3 (18.8) | 7 (43.8) | |